Scientech 02291 Prospectus Information

Company Overview

Stock Name	Scientech
Stock Code	02291
Company Full Name	To be extracted
Industry	Healthcare
Principal Activities	主要針對結構性心臟病的介入醫療器械的研發、生產及商業化，擁有20款已上市封堵器產品、9款封堵器在研產品以及21款主要心臟瓣膜在研產品
Listing Date	2022-11-08
Listing Rules Era	Old Rules
Listing Rules Chapter	To be extracted
Weighted Voting Rights (WVR)	No
Registered Address (Mainland China)	中國上海市松江區莘磚公路258號41幢201室
Business Address (Hong Kong)	香港銅鑼灣勿地臣街1號時代廣場2座31樓
Place of Incorporation	To be extracted
Listing Method	To be extracted
Listing Board	Main Board
Website	scientechmed.com
Share Registrar	卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact	(852)2980 1333
A-Share/US Dual Listing	No

Offering Information

Offering Mechanism	To be extracted
Offer Price	HK$ 29.15 / shares
Offer Price Range	Final offer price only, no range
Lot Size	1,000 shares
Entry Threshold	HK$ 29,150
Par Value	RMB 1.0 / shares
Offer Period	2022-10-27 to 2022-11-01
Global Offering Shares	22,455,000 shares
HK Public Offer Shares (Initial)	2,246,000 shares (10.0%)
Public Offer Lots (Initial)	2,246lots (Pool A1,123lots，Pool B1,123lots)
International Placing Shares (Initial)	20,209,000 shares (90.0%)
Offer Ratio	~10.0%
Total Shares Post-IPO	346,749,997 shares
Greenshoe (Over-allotment Option)	Yes
Stabilizing Manager (Greenshoe)	To be extracted
Cornerstone Share	29.7%
Clawback Tiers	To be extracted
Reallocation Option	Yes
Total Global Offering Size	HK$ 654,563,250

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A

Lots Subscribed	Shares Subscribed	Subscription Amount (HKD)
1 lots	1,000	HK$ 29,150
2 lots	2,000	HK$ 58,300
3 lots	3,000	HK$ 87,450
4 lots	4,000	HK$ 116,600
5 lots	5,000	HK$ 145,750
6 lots	6,000	HK$ 174,900
7 lots	7,000	HK$ 204,050
8 lots	8,000	HK$ 233,200
9 lots	9,000	HK$ 262,350
10 lots	10,000	HK$ 291,500
20 lots	20,000	HK$ 583,000
30 lots	30,000	HK$ 874,500
50 lots	50,000	HK$ 1,457,500
100 lots	100,000	HK$ 2,915,000

Pool B

Lots Subscribed	Shares Subscribed	Subscription Amount (HKD)
200 lots	200,000	HK$ 5,830,000
300 lots	300,000	HK$ 8,745,000
1,123 lots	1,123,000	HK$ 32,735,450

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway	Regular Path
HK Market Cap	HK$ 4.52B
Est. Threshold	HK$ 9.05B
Analysis Result	HK market cap below threshold, need +100%

Valuation & Financials

Market Cap (at Offer Price)	HK$ 10,107,762,412
Pre-IPO Valuation (Last Round)	Not disclosed
P/E Ratio	Not disclosed
Profit/Loss Status	盈利人民幣58.7百萬元
Period-End Cash Balance	To be extracted
Listing Expenses	To be extracted
Listing Expenses / Funds Raised	To be extracted
Total Pre-IPO Investment	To be extracted

Financial Data

Unit: '000 RMB

Income Statement

Item	2019	2020	2021
Revenue	116,451	148,247	222,583
Cost of sales	-13,619	-15,134	-25,038
Gross profit	102,832	133,113	197,545
Other income and gains, net	15,746	13,238	22,642
Selling and distribution expenses	-21,760	-23,146	-43,072
Administrative expenses	-8,981	-8,383	-59,874
Operating profit	60,219	76,537	76,387
Net finance costs	127	142	-10,360
Profit before tax	60,346	76,679	66,027
Income tax expense	-8,437	-7,907	-7,330
Profit for the year	51,909	68,772	58,697
Profit attributable to owners	51,909	68,772	58,697

Balance Sheet

Item	2019	2020	2021
Cash and cash equivalents	16,119	18,792	713,480
Trade and bills receivables	45,331	38,317	23,869
Inventories	11,052	23,319	33,402
Total current assets	85,944	105,762	792,516
Total assets	308,561	332,510	1,119,690
Total current liabilities	74,544	77,596	729,973
Total liabilities	76,692	78,911	734,499
Total equity	231,869	253,599	385,191
Equity attributable to owners	231,869	253,599	385,191

Cash Flow Statement

Item	2019	2020	2021	2022-06
Net cash from operating activities	54,475	59,097	105,278
Net cash from investing activities	-13,074	-8,463	-85,171
Net cash from financing activities	-41,864	-47,961	672,226
Net increase in cash	-463	2,673	692,333
Purchase of PP&E	-3,267	-2,525	-22,452	-9,461

Income Statement

Balance Sheet

Cash Flow Statement

Source: Accountants' Report and Audited Consolidated Financial Statements

First Day Close	HK$ 29.15
First Day Open	HK$ 29.8
First Day Change	-62.09%
First Day Volume	3807000.0
First Day Turnover	111634000.0
Use of Proceeds	1、約50.7%（或約287.6百萬港元）將用于為未來五年內的研發活動提供資金； 2、約24.3%（或約137.9百萬港元）將用于未來五年內的銷售及營銷活動； 3、約5.0%（或約28.4百萬港元）將用于在未來五年內提升產能及加強制造能力； 4、約10.0%（或約56.7百萬港元）將用于為未來五年內潛在的戰略投資及收購提供資金，以補充和擴大我們的產品組合及技術； 5、約10.0%（或約56.7百萬港元）將用于營運資金及一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)

China International Capital Corporation Hong Kong Securities Limited CE AEN894

Overall Coordinators (1)

China International Capital Corporation Hong Kong Securities Limited CE AEN894

Joint Bookrunners (5)

China International Capital Corporation Hong Kong Securities Limited CE AEN894 CLSA LIMITED CE AAB893 China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 VALUABLE CAPITAL LIMITED CE AUL711

Joint Lead Managers (5)

Cornerstone Investors

#	Investor Name	Investment Amount	Shares Subscribed	% of Offer Shares	% of Total Shares	Lock-up Period	Est. Unlock Date
1	Harvest International Premium Value (Secondary Market) Fund SPC	78,471,800 HKD	—	11.99%	—	6 months	2023-05-08
2	九州通国际集团有限公司	39,235,900 HKD	—	5.99%	—	6 months	2023-05-08
3	上海临港经济发展集团投资管理有限公司	76,897,700 HKD	—	11.75%	—	6 months	2023-05-08

Directors & Management

Position	Chinese name	English Name
Chairman	陳娟	—
Company Secretary	秦學、吳嘉雯	—

No director data available.

Major Shareholders

Major Shareholders & Holdings	樂普醫療（由蒲博士控制）持有本公司約86.34%權益，緊隨全球發售完成後約79.94%；蒲博士被視為擁有80.75%權益

Scientech 02291·IPOProspectus Information